kinesin family member 3AGenealiases: FLA10 · KLP-20
Q-omics provides the consensus-scored KIF3A profile across patient tissues and cancer cell-line models. KIF3A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KIF3A is differentially expressed in 14, with the highest sampling consensus in LIHC. Additionally, KIF3A protein abundance shows 21,707 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, LIHC, and GBM as cancer lineages where KIF3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIF3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIF3A survival associations across molecular data types. KIF3A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIF3A RNA expression–survival associations across cancer types. High KIF3A expression shows unfavorable associations in LIHC, CESC and HNSC, but favorable associations in KIRC, COAD and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KIF3A RNA expression.
This table summarizes KIF3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for KIF3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIF3A shows higher tumor expression in LIHC, HNSC, COAD, BRCA, CHOL and BLCA. The LIHC box plot shows higher KIF3A RNA expression in tumor versus normal tissue (log2 FC = +0.787, t-test p < 0.001).
This table shows molecular features associated with KIF3A in patient tissues and cancer cell lines. In patient samples, KIF3A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, KIF3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
